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involving a bifurcation site, restenotic lesions (including in-stent restenosis). two-vessel 
disease (a maximum of 2 lesions located in 2 different epicardial vessels), long lesions 
(up to 53 mm). 
Methods: The primary endpoint of the study is the Target Lesion Revascularization 
(TLR) rate at 160 days after stent implantation. Secondary endpoints are Target Vessel 
Failure (TVF) at 160-days, Major Cardiac Events (MACE) at 30-days and 160-days, 
MACE at l-year, P-years and 3-years in a subset of 500 patients, device succsss, procs- 
dure success and resource utilization. 
Results: As of abstract submission, data about 1252 patients enrolled at 60 investiga- 
tional sites is available for analysis, for a total of 1435 lesions treated. Among these, 374 
(34%) ware restenotic lesions. 
Conclusions: The patient recruitment in the DELIVER II study was completed on gt” of 
September 2002. Thirty-day safety results from the restenotic lesions subgroup will be 
available for presentation .and will be compared with the outcome of other lesion sub- 
groups. Multivariate analysis combining restenosis with other complicating factors will be 
presented as well. 
* Manufactured by Cook Incorporated. DELIVER II is conducted by Guidant Corporation 
on behalf of Cook Incorporated. 
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Background: Rapamycin, a maciolide antibiotic, inhibits SMC proliferation in vitro and in 
viva by blocking cell cycle progression at the GlIS transition. Given the anti-proliferative 
and anti-migratory properties of rapamycin, it may have anti-restenosis properties after 
PTCA and placement of coronary stsnts. Recently, implantation of rapamycin (sirolimus) 
eluting stems in de now lesions was shown to be safe and effective in inhibiting neointi- 
mal formation. The safety and efficacy of oral rapamycin in reducing the incidence of inti- 
mal hyperplasia and restsnosis is not known. 
Methods: Thirty Patients with stable exertional angina will receive standard therapy 
(ASA + Clopidegrol) plus rapamycin (loading dose 6 mg on the day of the procedure, fol- 
lowed by 2 mg/day) for either 2 (phase 1, n=15) or 4 (phase II, n=15) weeks after stent 
implantation for denovo lesions. Blood will be obtained for rapamycin levels, CBC, renal 
function and lipid profile. Quantitative coronary angiography @CA) and IVUS imaging 
will be performed immediately after the procedure and at a 6 month follow-up in all 
patients for evaluation of the primary endpoint of neointimal volume and binary resteno- 
sis. Results: To date, 15 (completed study-phase one) patients (mean age 60*10. 70% 
males, 27% diabetics, 40% prior MI) have been enrolled. All patients tolerated the load- 
ing dose plus two week course of oral Rapamycin without any significant side effects or 
laboratory abnormalities. There was one episode of recurrent in-hospital ischemia (few 
hours after the procedure) for suboptimal angiographic result which required further 
stenting. Angiographic and IVUS follow-up is in progress and will be presented for these 
patients as well as the full safety data on all 30 patients. 
1198-183 Oral Rapamune to Inhibit Restenosis in Patients With 
Multi De-Novo Coronary Lesions Requiring Stenting 
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Background: Drug-eluting stents (utilizing antiproliferative agents such as Rapamune) 
have shown the ability to limit restenosis. Oral Rapamune (R) is an alternative delivery 
strategy that can target multi-stenosed coronary vessels and may potentially lower the 
cost and vessel toxicity. 
Methods: The Cal Rapamune to Inhibit Restenosis (ORBIT) is an open label study of 
60 patients (pts) with de nova coronary artety stewsis treated with stent implantation in 
up to 2 vessels. The first 30 pts received R 2 mg /day for 30 days, and the last 30 pts 
received R 5mgIday for 30 days. The loading dose for both regimens was 5 mg given 
either immediately prior to or after the intervention. Patients underwent clinical and 
angiographic follow-up. 
Results: In the first 30 patients who received R 2 mg/day (age 60 * 10 years, 66% 
males, 13.3% diabetes), the mean number of treated lesions par pt was 1.6 f 0.5, with a 
reference vessel diameter of 3.0 r 0.5 mm and mean lesion length of 19.7 * 9.0 mm. 
Angiographic success was achieved in all pts. Mean pre-discharge serum R levels were 
5.1 f 3.1 ng/ml and at 30 days 6.5 + 4.2 (17 pts). Drug therapy was discontinued in 3 pts 
from the 2 mg group and in 5 pts from the 5 mg group due to skin rash, diarrhea, mouth 
ulcers, or fatigue (or a combination of these symptoms). There were no biological or bio- 
chemical adverse affects. 
In the 2 mg group, 49 lesions were treated. Of these, 40 were available for angiographic 
follow-up. The binary restenosis for in-stent was 5.0% and for in-segment was 7.5%. The 
late loss in-stent was 0.62 f 0.61 and the in-segment was 0.29 f 0.52 mm. Target lesion 
and vessel revascularization was 15.6%. Conclusions: Oral Rapamune administration 
for the prevention of restenosis is safe and feasible. Low rates of restenosis and late loss 
were observed with a dose of 2 mgiday. Complete g-month follow-up for the R 5mgld 
group will be available at presentation. 
1198-164 Stent Release of a Rapamycin Analogue: Tissue 
Pharmacoklnetics of Rapid Versus Delayed Release 
Frederick G. Walt, Elazer R. Edelman, Neda Vukmirovic, Campbell Rogers, Harvard- 
MIT, Cambridge, MA, Brigham and Woman’s Hospital, Boston, MA 
Bsckground:The effect of drug release rates from stents on tissue uptake and biologic 
effect are poorly understood. We investigated tissue distribution under varied release 
conditions of a stent-delivered rapamycin analogue. Methods and Resultsd6 rabbits 
underwent iliac artery stenting with a stent coated with a phospholylcholine polymer 
loaded with 3H drug (100 ).&tent). We compared 2 formulations: formulation l- rapid 
release, and formulation 2- slow release. Animals were harvested at 1. 3. 7, 14, and 28 
days and stent and tissue drug concentration determined through liquid scintillation 
counting. In viva drug release from formulation 1 was >90% at 3 days. Release from for- 
mulation 2 did not reach >90% until 14 days(P=0.005 by ANOVA). Arterial deposition 
peaked at 1 day with formulation 1 (726.0+154.3 pg/g tissue) and at 3 days in formulation 
2 (1339.0*412.6 pglg tissue). When plotted against percent of drug released from stew. 
efficiency of deposition (pg drug/g tissue/pg drug released) from formulation 2 was best 
fit by a polynomial equation (R* 0.64, p<O.OOl) and was greater (p=O.O4 by ANOVA) than 
efficiency from formulation 1 which was best fit by a linear equation (R2 0.56, 
p<O.OOl)(Figure). Conclusion: Delayed release enhances the efficiency of delivery of a 
rapamycin analogue to tha vessel wall. Modulating release may offer a more effective 
method of enhancing stent-based drug delivery than increasing dose. 
1198-l 85 Can Sirolimus-Elutlng Stents Tolerate Some Degree of 
Geographic Miss? 
Cherukupalli Raahu, Yves Louvard, Marie-Claude Morice, Carlo di Mario, Martin Leon, 
Jeffrey Moses, Judith Jaeger, Josef Ludwig, David Holmes, Antonio Colombo, lnstitut 
Cardiovasculaire Paris Sud, Massy, France, Centro Cuore Columbus, Milan, Italy 
Background. Sirolimus-eluting stems have proven their ability to almost completely sup- 
press 6.month neointimal proliferation in the stented segment. However, linls is known 
on the efficacy in the segments adjacent to the stent, dilated but not stented. 
Methods and Results. In a multicenter randomised bifurcation trial, between June 2001 
and April 2002, 66 pts with a significant stenosis at a bifurcation ware enrolled. The effi- 
cacy of sirolimus-eluting stents in these lesions has been evaluated. Pts were ran- 
domised into 2 groups of 43 each to receive either 2 stents (main vessel and branch) or 1 
stent (main vessel only). At the operator’s discretion 22 patients in the single stent arm 
have crossed over to the 2 stent arm. Baseline characteristics were comparable in both 
groups: mean age 63etO years, males 60.2%, diabetes 22%, and unstable angina 
17.4%. 
By means of QCA, films of 47 pts were analyzed before and after Intervention and at 6- 
months for the presence of geographic miss and its effect on restenosis. 5 patients who 
had acute procedural failure ware excluded from the analysis. Geographic miss has been 
defined as any balloon inflation beyond the non-stented segment. The segments proxi- 
mal and distal to the stent in the main vessel as well as the side branch have been exam- 
ined for geographic miss. 
Conclusion. Even in the era of drug-eluting stems, the process of restenosis is multifac- 
torial and the presence of geographic miss does not seem to influence the restanosis 
rates in bifurcation lesions. 
Study Group Restenosis 
No geographic miss (17/42) 6 (35%) 
Geographic miss (25/42) 4 (16%) 
Main vessel (10) 
Proximal to stent(4) 0 
Distal to stent (6) 1 
Side branch(l9) 3 
1198-186 Association Between Progression of Untreated 
Coronary Lesions and In-Stent Restenosis 
Dirk Skowasch, Joachim Vaerst, Alexander Jabs, Rend AndriB, Berndt Liideritz, Gerhard 
Baurisdel University of Bonn, Bonn, Germany -. 
Background: Progression of coronary artery disease is not completely understood, nei- 
ther for de-now stenoses nor for in-stent restenosis (ISR) as accelerated arteriosclero- 
sis. The objective of this angiographic study was to assess an association between 
presence of ISR and the progression of untreated coronary lesions. 
Methods: A Series of 212 high-grade native coronary stenoses (mean stenotic degree 
66%) of 150 patients was treated by stent implantation; 129 additional lesions with mild 
to moderate stenoses (>30%) remained untreated. Quantitative coronary angiography 
analysis was performed after 6+2 months regarding ISR (stenosis >50%), coronary pro- 
gression (increase in stenosis >20%) and regression (decrease >20%), rasp. Angio- 
graphic, procedural and clinical characteristics were assessed for a possible association 
to ISR and/or coronary progression. 
